Lasa Supergenerics Ltd. (LASA) AI Stock Analysis

• Market Cap: ₹589.69M
• Dividend Yield: N/A
• Average Volume (3M): 45.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: 25.82%
• EPS Growth: -69.86%
• Country: IN
• Employees: 77
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -4.21
• Shares Outstanding: 50,101,240
• 10 Day Avg. Volume: 49,497
• 30 Day Avg. Volume: 45,341
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹12.00
• Price Target Upside: 1.95% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 50 Neutral
• Price Target: ₹12.00 ▲(1.95% Upside)

Lasa Supergenerics Ltd. faces significant financial challenges with declining revenues and negative cash flows, which are the most impactful factors. Technical analysis provides some neutral signals, but the negative valuation metrics further weigh down the overall score.

Lasa Supergenerics Ltd. Business Overview & Revenue Model

Company Description

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers veterinary and other API products, anthelmintic products, animal feed ingredients, and reagents for therapeutic use. The company also exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Mumbai, India.

How the Company Makes Money

Lasa Supergenerics Ltd. generates revenue primarily through the sale of its APIs and intermediates to pharmaceutical companies and other clients in the healthcare industry. The company benefits from its strategic focus on the veterinary and human API markets, enabling it to capitalize on the growing demand for pharmaceutical ingredients. Revenue streams include direct sales to pharmaceutical manufacturers, contract manufacturing services, and the development of proprietary chemical processes that enhance production efficiency. Partnerships and collaborations with other pharmaceutical entities and research organizations also contribute to its revenue base, allowing Lasa to expand its market reach and enhance its product offerings.

Lasa Supergenerics Ltd. Financial Statement Overview

Summary

Lasa Supergenerics Ltd. is experiencing financial distress with declining revenues and persistent losses. The balance sheet shows manageable leverage but negative profitability metrics and cash flow issues pose significant risks.

Income Statement

Lasa Supergenerics Ltd. has faced declining revenues over the past years, with a negative revenue growth rate of approximately -30% from 2021 to 2025. The company's gross profit margin has also deteriorated significantly, indicating shrinking profitability. Furthermore, the net profit margin remains negative, which highlights persistent losses. The EBIT and EBITDA margins show negative trends, further stressing operational inefficiencies.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio, which suggests manageable leverage levels. However, the return on equity has been negative, reflecting the company's inability to generate profits from shareholder equity. The equity ratio remains relatively strong, suggesting a good proportion of assets financed by equity, though the overall financial health is challenged by persistent losses.

Cash Flow

Lasa's cash flow situation is concerning, with a negative free cash flow growth rate and negative operating cash flow in the latest period. The operating cash flow to net income ratio is negative, indicating cash flow issues in relation to net income. While the free cash flow to net income ratio is also negative, it highlights cash flow challenges that could impact future operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.26B	1.42B	1.04B	1.30B	1.37B	2.02B
Gross Profit	212.09M	362.61M	286.95M	-111.88M	427.84M	886.86M
EBITDA	-74.15M	-43.91M	-65.08M	-246.85M	84.12M	469.92M
Net Income	-157.66M	-147.57M	-217.31M	-386.21M	-53.31M	227.78M
Balance Sheet
Total Assets	0.00	1.02B	1.51B	1.64B	2.09B	2.08B
Cash, Cash Equivalents and Short-Term Investments	11.30M	7.90M	14.96M	21.78M	172.17M	44.00M
Total Debt	0.00	21.27M	220.76M	217.70M	201.71M	194.63M
Total Liabilities	-907.16M	178.19M	541.92M	455.69M	512.87M	489.43M
Stockholders Equity	907.16M	837.13M	966.76M	1.18B	1.58B	1.59B
Cash Flow
Free Cash Flow	0.00	-28.24M	21.39M	-173.00M	92.12M	347.24M
Operating Cash Flow	0.00	-28.24M	21.39M	-173.00M	92.12M	413.10M
Investing Cash Flow	0.00	81.52M	-3.98M	111.95M	-29.12M	-35.97M
Financing Cash Flow	0.00	-56.62M	-19.32M	-41.61M	-403.00K	-364.43M

Lasa Supergenerics Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.77
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LASA, the sentiment is Neutral. The current price of 11.77 is above the 20-day moving average (MA) of 11.45, above the 50-day MA of 10.68, and below the 200-day MA of 17.64, indicating a neutral trend. The MACD of 0.61 indicates Positive momentum. The RSI at 52.59 is Neutral, neither overbought nor oversold. The STOCH value of 21.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:LASA.

Lasa Supergenerics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BALAXI	64 Neutral	₹476.44M	11.90	10.82%	―	―	―
AAREYDRUGS	60 Neutral	₹2.23B	53.47	2.91%	―	-4.74%	-35.14%
BALPHARMA	60 Neutral	₹1.32B	15.58	9.32%	1.45%	-14.16%	10.85%
BIOFILCHEM	52 Neutral	₹679.76M	24.28	2.97%	―	-31.82%	341.44%
LASA	50 Neutral	₹589.69M	―	―	―	25.82%	-69.86%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Lasa Supergenerics Ltd. Corporate Events

Lasa Supergenerics Announces Key Decisions from Board Meeting

Lasa Supergenerics Ltd. held a board meeting on September 5, 2025, where several key decisions were made. The board approved the notice for the company’s 10th Annual General Meeting, scheduled for September 30, 2025, to be conducted via video conferencing. Additionally, the board approved the Director’s Report and related documents for the financial year ending March 31, 2025, appointed Shravan A. Gupta & Associates as the scrutinizer for the AGM, and re-appointed Mr. Omkar Herlekar as a director. The company also announced the closure of its Register of Members and Share Transfer Books from September 23 to September 29, 2025.